The ARCADIA trial (Alleviation of cardioRespiratory complications in patients with COVID-19 And DIAbetes) using AZD1656

SGS正寻求使用一种新药AZD1656进行临床试验，以治疗患有新冠肺炎的糖尿病患者。AZD1656最初是用于治疗肾移植排斥反应的潜在药物，但据推测，同样的机制可以减少免疫系统的过度炎症，同样适用于那些患有严重冠状病毒感染的人。临床观察表明，冠状病毒携带者可以经历两个疾病阶段。第一阶段是免疫系统对病毒感染做出适当的反应。对许多人来说，这是成功的，患者在一周后开始感觉好一些。然而，一些人的免疫系统反应过度，他们进入了疾病的第二阶段，即身体自身的免疫系统开始损害重要器官，如肺部。我们对新冠肺炎的潜在治疗旨在利用人体自身的机制，通过激活T调节细胞来控制过度的炎症。这些T调节细胞迁移到炎症部位，如肺部，有效地抑制多余的炎症，以减少器官损伤。此外，在临床试验中，AZD1656已被证明可以降低糖尿病患者的血糖。由于许多生物因素，I型和II型糖尿病患者出现更严重新冠肺炎症状的风险更高，血糖控制是其中一个重要因素。圣乔治街的目标是在2020年7月开始临床试验，由于当前大流行的紧迫性，这一时间表大大加快了。阿斯利康将免费向SGS提供配方药物产品，SGS将领导临床试验，在3个月的时间内在英国的医院招募150名患者。这项试验通过治疗AZD1656患者的主要目标是减少新冠肺炎糖尿病患者下降和进展到ICU的数量。

SGS is looking to run a clinical trial using a new drug, AZD1656 to treat diabetic patients suffering with COVID-19\. The potential drug AZD1656 was originally being explored for renal transplant rejection but it is hypothesised that the same mechanism of reducing excessive inflammation by the immune system could equally apply to those with severe coronavirus infection. Clinical observations have shown people with coronavirus can go through two stages of the disease. The first stage is an appropriate response of the immune system to fight the viral infection. In many people this is successful, and patients start to feel better after a week. In some people however the immune system overreacts, and they enter a second stage of the disease called 'hyperinflammation', where the body's own immune system starts to damage vital organs such as the lungs. Our potential treatment for COVID-19 aims to use the body's own mechanism of controlling excess inflammation by activating T regulatory cells. These T regulatory cells migrate to sites of inflammation such as the lungs, effectively dampening down the excess inflammation to reduce organ damage. In addition, AZD1656 has been shown to reduce blood glucose in patients with diabetes in clinical trials. Patients with both type I and type II diabetes are believed to be at higher risk of having more severe COVID-19 symptoms due to a number of biological factors, with blood glucose control being an important one. St George Street is aiming to start the clinical trial in July 2020, a vastly accelerated timescale driven by the urgency of the current pandemic. AstraZeneca will supply the formulated drug product at no cost to SGS and SGS will lead the clinical trial, enrolling 150 patients in hospitals in the UK over a 3-month timeframe. The primary objective of the trial through treating patients with AZD1656 is to reduce the number of diabetic patients with COVID-19 who decline and progress to the ICU.